FDA Approves OncoSil Device for Unresectable Distal Cholangiocarcinoma

The US Food and Drug Administration (FDA) has granted Humanitarian Device Exemption (HDE) approval for the OncoSil device. The implantable medical device is indicated for the treatment of patients over 21 years of age with distal cholangiocarcinoma (dCCA) that is both unresectable (locally advanced and/or unfit for surgery) and non-metastatic, as an adjunct to systemic chemotherapy. This decision establishes OncoSil as the first FDA-approved Class III medical device specifically indicated for dCCA, providing a new therapeutic pathway for patients with high unmet clinical needs.

Distal cholangiocarcinoma is a rare, highly aggressive malignancy that arises in the distal common bile duct, located in the head of the pancreas. Because early symptoms are often absent, dCCA is frequently diagnosed at an advanced stage when surgical removal is no longer possible, leaving more than 50% of patients ineligible for potentially curative resection. For patients with unresectable, non-metastatic disease, the prognosis is poor, with a reported median overall survival of approximately 6.7 months. Data suggest that dCCA incidence is rising by approximately 1.4% annually.

Traditional management of unresectable dCCA typically involves biliary stenting to maintain bile duct patency, combined with systemic chemotherapy and, in selected cases, external beam radiation therapy. However, disease progression often leads to severe localized complications, including recurrent biliary obstruction, stent occlusion, and cholangitis. These complications frequently result in acute hospitalizations, interrupting systemic chemotherapy and severely degrading the patient’s quality of life. Achieving local tumor control to prevent these obstructive events is therefore a key therapeutic priority.

The newly approved OncoSil device is an interventional oncology technology designed for single-patient, single-use intratumoral implantation. Under endoscopic ultrasound (EUS) guidance, the device is injected directly into the solid tumor. It delivers a targeted dose of radiation using Phosphorus-32 (32P) microparticles. This localized, selective placement allows clinicians to deliver a greater radiation dose directly into the tumor compared to external beam radiotherapy, while sparing adjacent critical organs and healthy surrounding tissue.

Because dCCA is a rare condition—affecting a subset of the estimated 8,000 individuals diagnosed with cholangiocarcinoma in the US each year—the OncoSil device was reviewed under the FDA’s HDE pathway. The HDE pathway provides a regulatory mechanism for devices designed to treat or diagnose conditions affecting no more than 8,000 individuals in the US annually.

Unlike the traditional Premarket Approval (PMA) pathway, an HDE does not require clinical trials demonstrating a reasonable assurance of effectiveness. Instead, the FDA must determine that the device does not pose an unreasonable or significant risk, and that its probable clinical benefit outweighs the risks of its use. Out of the broader cholangiocarcinoma population, dCCA accounts for approximately 30% to 40% of cases. The subset of patients meeting the criteria for unresectable, non-metastatic dCCA represents an annual addressable patient pool of approximately 1,000 individuals in the US.

As a condition of the HDE approval, the use and distribution of OncoSil in the US will initially be restricted to a maximum of five treatment centers with appropriately trained multidisciplinary practitioners. This controlled rollout will occur as part of an FDA-required Post-Approval Study (PAS). The PAS will be a prospective, multicenter study designed to evaluate the safety and probable benefit of the OncoSil device in 30 patients followed for up to 24 months.

Oncology nurses are essential in coordinating the multidisciplinary care required for interventional EUS-guided implantation and subsequent clinical monitoring. Nurses must coordinate care across interventional endoscopists, radiation oncologists, medical oncologists, and nuclear medicine specialists. Additionally, because the therapy involves radioactive Phosphorus-32, oncology nurses are central to ensuring patient safety, managing localized and systemic treatment toxicities, and educating patients on post-implantation care.

Nurses are also on the front lines of identifying early signs of stent occlusion and cholangitis, ensuring that any obstructive complications are caught early to prevent treatment interruptions and preserve patient safety. OncoSil Medical plans to launch the device in the US in the second half of fiscal year 2027, with clinician education and training programs beginning ahead of the commercial release.

References

1. OncoSil™ Device Receives U.S. FDA Approval for Distal Cholangiocarcinoma. ASX Announcement. Sydney, Australia: OncoSil Medical Limited; August 17, 2026